ResidentRochester General HospitalRochester, New York, United States
OC 42.5 - Hemorrhagic risk of Caplacizumab in the treatment of Thrombotic thrombocytopenic purpura A pharmacovigilance study from 2020-2022 FAERS Database.
Monday, June 26, 202315:45 – 16:00 ET